Koninklijke Philips N.V.(PHG) Stock Research - Grey Stern Research
Loading...

Koninklijke Philips N.V. (PHG) Stock Analysis

$27.98 (1.89%)

PHG Financial Performance


Use the table below to view Koninklijke Philips N.V.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from -

Metric Value Ranking among Peers
Price $27.46 -
52 Week Low $17.75 -
52 Week High $29.44 -
Market Cap $24.9 Billion 7/20
Gross Margin 36% 19/20
Profit Margin 1% 13/20
EBITDA margin -1% 13/20
- Revenue $5.6 Billion 4/20
- Earnings $42.9 Million 9/20
- Free Cash Flow $0 Million 20/20
Trailing 4 Quarters Revenue $20.0 Billion 5/20
Trailing 4 Quarters Earnings -$509.9 Million 19/20
Quarterly Earnings Growth 135% 5/20
Annual Earnings Growth 89% 5/20
Quarterly Revenue Growth -7% 19/20
Annual Revenue Growth -1% 17/20
Cash On Hand $2.1 Billion 2/20
Short Term Debt $718.7 Million 5/20
Long Term Debt $7.6 Billion 5/20

Koninklijke Philips N.V. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Koninklijke Philips N.V.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 14/20
PS 1.13 18/20
PB 1.88 17/20
PC 12.12 16/20
Liabilities to Equity 1.44 6/20
ROA -0.02 14/20
ROE -0.04 16/20
Current Ratio 1.70 13/20
Quick Ratio 0.11 11/20
Long Term Debt to Equity 0.58 9/20
Debt to Equity 0.63 9/20
Burn Rate 4.68 5/20
Cash to Cap 0.08 3/20
CCR 20/20
EV to EBITDA -590.99 19/20
EV to Revenue 1.66 18/20

Company Details

Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

CEO: Mr. Franois Adrianus van Houten

Website: https://www.philips.com

Address: Philips Center Amsterdam,

Exchange: New York Stock Exchange

Industry: Medical Devices

Koninklijke Philips N.V. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Koninklijke Philips N.V.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Boston Scientific Corporation BSX $109.7 Billion
Abbott Laboratories ABT $181.1 Billion
Medtronic plc MDT $114.1 Billion
Glaukos Corporation GKOS $5.5 Billion
Zimmer Biomet Holdings, Inc. ZBH $24.7 Billion
Edwards Lifesciences Corporation EW $53.7 Billion
Stryker Corporation SYK $127.5 Billion
Insulet Corporation PODD $13.1 Billion
Bruker Corporation BRKR $10.9 Billion
NuVasive, Inc. NUVA $2.1 Billion
STERIS plc STE $23.0 Billion
NovoCure Limited NVCR $2.4 Billion
Globus Medical, Inc. GMED $8.7 Billion
Bio-Rad Laboratories, Inc. BIO $8.4 Billion
Integer Holdings Corporation ITGR $4.1 Billion
CONMED Corporation CNMD $2.3 Billion
Inspire Medical Systems, Inc. INSP $4.6 Billion
Inari Medical, Inc. NARI $2.7 Billion
ZimVie Inc. ZIMV $464.5 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
PHG Income Statements
Quarter Year Revenue Earnings
Q4 2023 € 5.1 Billion €39.0 Million
Q3 2023 € 4.5 Billion €88.0 Million
Q2 2023 € 4.5 Billion €72.0 Million
Q1 2023 € 4.2 Billion -€663.0 Million
Q4 2022 € 5.4 Billion -€113.0 Million
Q3 2022 € 4.3 Billion -€1.3 Billion
Q2 2022 € 4.2 Billion -€22.0 Million
Q1 2022 € 3.9 Billion -€151.0 Million

View All

PHG Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2023 €1.9 Billion €29.4 Billion €7.6 Billion €12.1 Billion
Q3 2023 €968.0 Million €0 €0 €12.2 Billion
Q2 2023 €960.0 Million €29.5 Billion €8.2 Billion €12.1 Billion
Q1 2023 $1.1 Billion $1.1 Billion $16.4 Billion -$15.2 Billion
Q4 2022 €1.2 Billion €30.7 Billion €8.2 Billion €13.2 Billion
Q3 2022 €1.3 Billion €0 €0 €14.8 Billion
Q2 2022 €1.3 Billion €32.5 Billion €8.0 Billion €14.8 Billion
Q4 2021 €2.3 Billion €31.0 Billion €7.0 Billion €14.5 Billion

View All

PHG Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2020 €0 €0 €0
Q3 2020 €0 €0 €0
Q4 2016 €828.0 Million -€248.0 Million €475.0 Million
Q3 2016 €266.0 Million -€234.0 Million -€67.0 Million
Q2 2016 €124.0 Million -€194.0 Million €541.0 Million
Q1 2016 -€183.0 Million -€193.0 Million -€381.0 Million
Q4 2015 €669.0 Million -€287.0 Million €741.0 Million
Q3 2015 €30.0 Million -€251.0 Million -€110.0 Million

View All